

# Greater Manchester Joint Formulary & RAG/DNP list change log

09 November 2023

The list below includes changes made in the last 12 months. For information on older updates, contact [nuth.enquiries.gmmmg@nhs.net](mailto:nuth.enquiries.gmmmg@nhs.net)



Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
09/11/2023	1	1.5.3	Upadacitinib for previously treated moderately to severely active Crohn's disease added as RED, as per TA905	Y	Y	7.11
09/11/2023	2	2.12	MHRA DSU link added: Statins: very infrequent reports of myasthenia gravis (Sept 2023)	n/a	Y	7.20
09/11/2023	2	2.5.5.1	Dapagliflozin for chronic heart failure with preserved or mildly reduce ejection fraction added as GREEN (following	Y	Y	7.20
09/11/2023	13	13.5.3	Deucravactinib for moderate to severe plaque psoriasis added as per NICE TA907	Y	Y	6.9
01/11/2023	4	4.3.4	DNP entry for esketamine amended to add link to terminated NICE TA899 for major depressive disorder with imminent	Y	Y	9.20
01/11/2023	5	5.3.3	Bulvertide added as RED, as per NICE TA896	Y	Y	7.7
01/11/2023	RAG		Link to NICE CG57 added to paediatric RAG list entry for emollient bath additives.	Y	n/a	n/a
30/10/2023	13	13.4	Error corrected - hydrocortisone 0.5% cream removed from DNP list, replaced with 0.5% ointment	Y	n/a	n/a
05/10/2023	1	1.5.3	Infliximab SC solution added as RED, for use as per other infliximab preparations	n/a	Y	7.10
05/10/2023	1	1.5.3	Vedolizumab SC solution added as RED, for use as per other vedolizumab preparations	n/a	Y	7.10
05/10/2023	1	1.5.3	Risankizumab for Crohn's disease added as RED, as per NICE TA888.	n/a	Y	7.10
05/10/2023	2	2.2, 2.4	Links to NICE CG127 removed and replaced with links to NG136, which superseded it.	n/a	Y	7.19
05/10/2023	6	6.1.2.3	Links to NG18 added alongside liraglutide, dulaglutide, empagliflozin	n/a	Y	9.26
05/10/2023	10	10.1.3	Infliximab SC solution added as RED, for use as per other infliximab preparations	n/a	Y	7.17
05/10/2023	13	13.4	Hydrocortisone 0.5% cream and 2.5% cream and ointment added to DNP list (criterion 2)	Y	Y	6.8
02/10/2023	8	8.2.2	Voclosporin added as RED, as per NICE TA882	Y	Y	12.7
02/10/2023	13	13.1	Difelikefalin added as RED, as per NICE TA890	Y	Y	6.7
28/09/2023	1	1.2	MHRA DSU link added: Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of anticholinergic side effects, including hyperthermia (July 2023)	n/a	Y	7.9
28/09/2023	1	1.5.3	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (August 2023)	n/a	Y	7.9
28/09/2023	4	4.6	MHRA DSU link added: Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of anticholinergic side effects, including hyperthermia (July 2023)	n/a	Y	9.19
28/09/2023	4	4.2.3 & 4.8.1	MHRA DSU link added: Valproate: re-analysis of study on risks in children of men taking valproate (August 2023)	n/a	Y	9.19
28/09/2023	8	8	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions	n/a	Y	12.6
28/09/2023	10	10.1.3	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions	n/a	Y	7.16
28/09/2023	13	13.5.1	MHRA DSU link added: Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials	n/a	Y	6.6
28/09/2023	13	13.5.3	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (August 2023)	n/a	Y	6.6
15/09/2023	6	6.1	Links added to GM guidance on managing GLP-1 shortages in T2DM	Y	Y	9.25
01/09/2023	2	2.5	Link added to new GMMMG hypertension pathway	n/a	Y	7.17

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
01/09/2023	3	3.4.2	Tezepelumab added as RED as per NICE TA880: Tezepelumab for treating severe asthma	Y	Y	8.8
01/09/2023	6	6.1.1.2	Statements on GLP-1 shortages added to the intermediate, long-acting and biphasic insulin sections, with links SPS advice on managing shortages	n/a	Y	9.24
01/09/2023	6	6.1.1.2	Toujeo updated to GREEN (was previously green specialist advice and GREY) to support management of GLP-1	Y	Y	9.24
01/09/2023	6	6.1.1.2	Insulin cost charts updated	n/a	Y	9.24
01/09/2023	6	6.1.1.3	Insulin need cost chart updated	n/a	Y	9.24
01/09/2023	6	6.1.2.3	Statement on GLP-1 shortages added to the GLP-1 section, with cross-reference to insulin section and link to SPS advice	n/a	Y	9.24
01/09/2023	RAG		Fosfomycin for uncomplicated UTI changed to GREEN (was green specialist advice)	Y	n/a	n/a
23/08/2023	6	6.1.6	Dexcom ONE and Freestyle Libre 2 added to formulary	n/a	Y	9.23
07/08/2023	2	2.2.3	Finerenone added as GREEN (specialist advice) for CKD in type 2 diabetes, as per NICE TA877.	Y	Y	7.16
07/08/2023	4	4.5.1	Semaglutide injection added as RED, for prescribing by specialist weight management services only as per NICE TA875:	Y	Y	9.18
07/08/2023	4	4.7.2	Actimorph - add as GREEN and GREY, as an alternative to morphine sulfate tablets or oral solution 10mg/5ml	Y	Y	9.18
07/08/2023	4	4.7.4.2	Eptinezumab added as RED as per NICE TA871: Eptinezumab for preventing migraine	Y	Y	9.18
07/08/2023	6	6.3.2	Efmody added as Green (following specialist initiation) as an alternative option, only for patients not well controlled on standard release hydrocortisone and where specified criteria are met.	Y	Y	9.22
07/08/2023	RAG		Dapagliflozin added to paediatric RAG list for CKD 2-3 as RED	Y	n/a	n/a
28/07/2023	2	2.12	Typo corrected: bempedoic acid amended to Greep (specialist advice), aligning with CRG decision and RAG list	n/a	Y	7.15
28/07/2023	3	3.4.3	MHRA DSU link added: Adrenaline auto-injectors (AAIs): new guidance and resources for safe use, June 2023	n/a	Y	8.7
28/07/2023	4	4.1 & 4.7	MHRA DSU link added: Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy, June 2023	n/a	Y	9.17
28/07/2023	4	4.8.1	Link added to NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex	n/a	Y	9.17
28/07/2023	5	5.1.7	Bezlotoxumab entry amended to remove link to retired HCD commissioning statement	Y	Y	7.6
28/07/2023	9	9.2.1.1	MHRA DSU link added: Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in	n/a	Y	6.7
28/07/2023	10	10.1.1	MHRA DSU link added: Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after	n/a	Y	7.15
28/07/2023	RAG		Chloral hydrate and cloral betaine added as RED	Y	n/a	n/a
28/07/2023	RAG		Asfotase alfa added as RED as per NICE HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia	Y	n/a	n/a
29/06/2023	2	2.9	Note added: "do not routinely offer aspirin for primary prevention of CVD", with link to CG181.	n/a	Y	7.14
29/06/2023	6	6.5.1	Somatrogen added as RED (pending shared care) as per NICE TA863	Y	Y	9.21
29/06/2023	10	10.1.3	NICE TA861, upadacitinib for non-radiographic axial spondyloarthritis, added as RED	Y	Y	7.14
29/06/2023	RAG		Vutisiran added as RED, as per NICE TA868	Y	n/a	n/a
29/06/2023	RAG		Ataluren added as RED, as per NST 22	Y	n/a	n/a
12/06/2023	6	6.1.2.2	Metformin 1g immediate-release tablets added to DNP list, criterion 2	Y	Y	9.20
06/06/2023	RAG		Typo corrected: upadacitinib TA856 corrected to read ulcerative colitis	Y	n/a	n/a
26/05/2023	1	1.5.3	Upadacitinib added as RED, in line with TA856	Y	Y	7.8

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
26/05/2023	1	1.5.3	MHRA DSU link added: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality. April 23	n/a	Y	7.8
26/05/2023	1	Misc	IQoro neuromuscular training device added to DNP list, criterion 1	Y	Y	7.8
26/05/2023	2	2.12	Colestyramine and colesevelam for CVD prevention in hyperlipidaemia added to grey list as green (specialist advice),	Y	Y	7.13
26/05/2023	5	5.3.2.2	Maribavir added as RED, in line with TA860	Y	Y	7.5
26/05/2023	6	6.1	Following preparations removed from formulary following discontinuation:	n/a	Y	6.19
26/05/2023	10	10.1.3	MHRA DSU link added: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality. April 23	n/a	Y	7.13
26/05/2023	13	13.11.6	Potassium permanganate assigned RED RAG status	Y	Y	6.5
26/05/2023	13	13.5.3	MHRA DSU link added: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events,	n/a	Y	6.5
26/05/2023	13	13.6.1	Trifarotene for acne added to formulary as GREEN	Y	Y	6.5
26/05/2023	13	13.6.2	MHRA DSU link added: Isotretinoin (Roaccutane ▼): new safety measures to be introduced in the coming months,	n/a	Y	6.5
24/05/2023	RAG		RAG list updated to add sotrovimab, to align with formulary entry added in May 2022.	Y	n/a	n/a
24/04/2023	4	4.10.1	Links to NICE guidance updated to correct broken link.	n/a	Y	9.15
24/04/2023	4	4.3.4	Esketamine nasal spray added to DNP list, as per NICE TA854: Esketamine nasal spray for treatment-resistant	Y	Y	9.15
24/04/2023	6	6.2.1	Link added to NICE NG230: Thyroid cancer: assessment and management	n/a	Y	9.18
24/04/2023	6	6.4.1	Link added to Joint BMS FSRH RCGP RCOG SfE and RCN Women's Health Forum safety alert on doses of oestrogen	n/a	Y	9.18
24/04/2023	9	9.1.4	Link added to NICE TA853, avatrombopag for primary chronic immune thrombocytopenia	Y	Y	6.6
16/03/2023	1	1.5.3	Ozanimod for UC added as RED, in line with NICE TA828	Y	Y	7.7
16/03/2023	6	6.1.1.2	Insulin cost charts updated	n/a	Y	9.16
16/03/2023	6	6.1.1.3	Insulin needle cost chart updated	n/a	Y	9.16
16/03/2023	6	6.4.2	MHRA DSU link added: Topical testosterone (Testogel): risk of harm to children following accidental exposure. Jan	Y	Y	9.16
16/03/2023	6	6.7.2	Reuligolix/estradiol/norethisterone for fibroids added as GREEN (specialist advice) in line with NICE TA832	Y	Y	9.16
16/03/2023	10	10.1.3	Upadacitinib for active AS added as RED, in line with NICE TA829	n/a	Y	7.11
16/03/2023	11	11.4.1	Links to TA349 (dexamethasone for DMO) removed and replaced with links to TA824	n/a	Y	5.5
16/03/2023	RAG		Avacopan added as RED, in line with NICE TA825	Y	n/a	n/a
21/02/2023	9	9.1.4	Fostamatinib removed from DNP list and added to formulary as a RED drug, in line with NICE TA835	Y	Y	6.5
21/02/2023	10	10.1.1	Links to CG177 removed and replaced with links to updated guidance NG226.	n/a	Y	7.10
21/02/2023	10	10.1.5	Links to CG177 removed and replaced with links to updated guidance NG226. Advice on glucosamine and chondroitin replaced with updated advice on glucosamine and opioids.	n/a	Y	7.10

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
21/02/2023	RAG		MHRA DSU link added: Xaquia (metolazone) 5mg tablets: exercise caution when switching patients between	Y	n/a	n/a
25/01/2023	RAG		Pentosan RAG status updated to RED, in line with FMESG decision from Jan 2020 and formulary position.	Y	n/a	n/a
23/01/2023	6	6.4	Minor corrections to links and formatting, in line with new HRT pathway	n/a	Y	9.15
17/01/2023	1	1.2	Medicines added to formulary to reflect newly approved hypersalivation guidance: hyoscine tablets and patches, atropine eye drops, glycopyrronium oral solution.	Y	Y	7.6
17/01/2023	6	6.1.1.1	Insuman Comb 50 removed from formulary - product discontinued	n/a	Y	9.14
17/01/2023	6	6.4.1	Section updated to reflect HRT guidance: addition of Bijuve, Elleste Duet Conti, tibolone, Estradot, Oestrogel, Sandrena,	n/a	Y	9.14
17/01/2023	6	6.4.2	Section updated to reflect HRT guidance: testosterone for low sexual desire in post-menopausal women updated to	Y	Y	9.14
17/01/2023	7	7.2.1	Section updated to reflect HRT guidance: Gynest, Ortho-Gynest & Vagifem removed; Ovestin, Imvaggis, Vagirux, Estring added.	n/a	Y	7.2
17/01/2023	10	10.1.3	Links to NICE TA711 (guselkumab for psoriatic arthritis) removed and replaced with links to updated NICE TA815	Y	Y	7.9
17/01/2023	11	11.8.2.3	NICE TA820, brolocizumab for diabetic macular oedema, added	Y	Y	5.4
17/01/2023	13	13.5.3	Abrocitinib, tralokinumab & upadacitinib added as RED drugs, in line with NICE TA814	Y	Y	6.4
19/12/2022	1	1.3.1	Famotidine 20mg & 40 mg tablets added to formulary as GREEN as first choice H2 receptor antagonist replacing ranitidine.	Y	Y	7.5
19/12/2022	2	2.12	Icosapent ethyl added as GREEN (specialist advice) as per NICE TA805: Icosapent ethyl with statin therapy for reducing	Y	Y	7.12
19/12/2022	2	2.12	Black triangle added against inclisiran	n/a	Y	7.12
19/12/2022	4	4.4	Modafinil RAG status updated to GREEN (following specialist initiation) following publication of information for primary care prescribers.	Y	Y	9.13
19/12/2022	4	4.2.1	RAG status for lurasidone updated to AMBER following publication of updated shared care protocol for atypical antipsychotics	Y	Y	9.14
19/12/2022	4	4.2.1	Paliperidone MR tablets added to formulary with AMBER status, in line with updated SCP	Y	Y	9.14
19/12/2022	4	4.8.1	Fenfluramine added as a RED drug as per NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome	Y	Y	9.14
19/12/2022	8	8.2	Imlifidase added as a RED drug as per NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease	Y	Y	12.5
19/12/2022	9	9.1.3	Roxadustat added as RED as per NICE TA807: Roxadustat for treating symptomatic anaemia in chronic kidney disease	Y	Y	6.4
19/12/2022	9	9.2.1.1	Sodium zirconium cyclosilicate and patiomer sodium for hyperkalemia both updated to AMBER following publication of shared care protocols.	Y	Y	6.4
19/12/2022	10	10.1.3	Risankizumab added as RED per NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs	n/a	Y	7.8
19/12/2022	RAG	RAG	Metolazone - removed reference to unlicensed product, and added recommendation for brand name prescribing.	Y	n/a	n/a
19/12/2022	RAG	RAG	Add setmelanotide as RED as per NICE HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency <a href="https://www.nice.org.uk/guidance/hst21">https://www.nice.org.uk/guidance/hst21</a>	Y	n/a	n/a
16/12/2022	1	1.5.2	Budesonide MR - amended to remove advice on specialist initiation, and add MGSG decision "counselling on the safe	Y	Y	7.4

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
16/12/2022	3	3.4.2	MHRA DSU link added: Dupilumab Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt	n/a	Y	8.6
16/12/2022	6	6.1.2.3	Tirzepatide - statement added to clarify that tirzepatide has not considered by GMMMG pending NICE and shouldn't	Y	Y	9.13
16/12/2022	13	13.5.3	MHRA DSU link added: Dupilumab Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt	n/a	Y	6.3
24/11/2022	1	1.5	Filgotinib added as RED for moderately to severely active ulcerative colitis, in line with NICE TA792	Y	Y	7.3
24/11/2022	1	1.5	Black triangle against Amgevita (adalimumab) removed; no longer applies to this product.	n/a	Y	7.3
24/11/2022	1	1.4.2	Teduglutide added as a RED drug, in line with NICE TA804	Y	Y	7.3
24/11/2022	2	2.3.2	Mexiletine for life-threatening ventricular arrhythmias added as RED	Y	Y	7.11
24/11/2022	4	4.3	Links to superseded NICE guideline CG90 removed and replaced with link so NG222: Depression in adults.	n/a	Y	9.12
24/11/2022	4	4.4	MHRA DSU link added: Methyphenidate long-acting (modified-release) preparations: caution if switching between	n/a	Y	9.12
24/11/2022	4	4.1.1	Adaflex added to formulary as first choice melatonin product.	Y	Y	9.12
24/11/2022	8	8.2.4	Black triangle for canakinumab removed; no longer applies to this product	n/a	Y	12.4
24/11/2022	8	8.2.4	Diroximel fumarate added as RED, in line with NICE TA794: diroximel fumarate for treating relapsing–remitting		Y	12.4
24/11/2022	8	8.2.4	Link to NHSE commissioning policy multiple sclerosis updated	n/a	Y	12.4
24/11/2022	8	8.2.4	Link added to NICE NG220: Multiple sclerosis in adults: management	n/a	Y	12.4
24/11/2022	10	10.1.4	Link to superseded NICE TA164 (febuxostat for gout) removed and replaced with links to NICE NG219: Gout diagnosis and management.	n/a	Y	7.7
24/11/2022	11	11.8.2.2	Ranibizimab biosimilar added to formulary as first choice VEGF-A for NICE-approved indications	n/a	Y	5.3
24/11/2022	11	11.8.2.2	Faricimab added as RED in line with NICE TA799 & TA800	Y	Y	5.3